Latest filing published 13 Nov 2023 for Intercept Pharmaceuticals, INC., €504k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by M. Michelle Berrey on record concern Intercept Pharmaceuticals, Inc., in the capacity of chief executive. Over a trading history stretching from 14 June 2021 to 8 November 2023, the count stands at 11 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The record was last updated on 13 November 2023 with a transaction (€504k) in Intercept Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations